Immunic
IMUX· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -33.3% in FY2024
Dr. Daniel Vitt is the CEO of Immunic and was paid $2.9M in FY2024 (Dec), up 142%.
Pay$100 in the stock at the end of FY22 → $71
Executives5
See all- 1Dr. Daniel VittChief Executive OfficerFY2024
- 2Dr. Andreas MuehlerChief Medical OfficerFY2024
- 3Dr. Duane D. NashExecutive ChairmanFY2024
- 4Glenn WhaleyChief Financial OfficerFY2024
- 5Jason TardioCOO and PresidentFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allImmunic paid its 5 named executives $7.7M in total in FY2024 (Dec). CEO Dr. Daniel Vitt was paid $2.9M of that.
| Name | ||
|---|---|---|
| Dr. Daniel VittChief Executive Officer | ||
| Dr. Andreas MuehlerChief Medical Officer | ||
| Dr. Duane D. NashExecutive Chairman | ||
| Glenn WhaleyChief Financial Officer | ||
| Jason TardioCOO and President | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Immunic. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Jörg NeermannDirector · 5 yr on the boardIndependentAudit, Nominating and Governance (Chair)—Paid as an executive
- Richard RudickDirector · 1 yr on the boardIndependentCompensation, Nominating and Governance—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 2, 2026 | — |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Annual report | 10-K | Feb 22, 2024 | FY2023 |
| Proxy statement | DEF 14A | Feb 5, 2024 | — |
